Owlet makes FDA-cleared wearable infant health monitors for home use. The core product, Dream Sock, is a pulse oximetry sensor worn on a baby's foot that tracks pulse rate, blood oxygen levels, activity, and sleep, sending real-time alerts to parents via a smartphone app. Dream Sock is the first and only FDA-cleared over-the-counter infant health monitor in the U.S. Owlet also sells Dream Sight, an HD video and audio baby monitor, and bundles the two as Dream Duo. A prescription-only variant, BabySat, targets higher-risk infants under physician supervision and is designed to be reimbursable through insurance and Medicaid. Owlet sells through direct-to-consumer digital channels and major U.S. retailers including Amazon, Target, Walmart, and Best Buy, with international distribution across Canada, the UK, Australia, and the EU. Owlet's business model is primarily hardware-driven, with one-time device purchases representing the large majority of revenue. The company is building a recurring revenue layer through Owlet360, a $9.99/month subscription launched in January 2025 that provides personalized pediatric health analytics; Owlet reached over 110,000 paying subscribers by early March 2026. Longer-term, Owlet is expanding into healthcare channels via BabySat insurance reimbursement, a planned telehealth platform that integrates Dream Sock biometric data, and AI-driven features built on its proprietary pediatric dataset. Owlet's hardware is manufactured in Thailand and Vietnam, creating tariff exposure the company is working to reduce through a planned expansion of manufacturing to Mexico.